EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium-Reference-Cited by-同舟云学术

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium

Published:2008-06 Issue:25 Volume:26 Page:3153-3161
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Bart Pierre-Alexandre,Goodall Ruth,Barber Tristan,Harari Alexandre,Guimaraes-Walker Ana,Khonkarly Mona,Sheppard Neil C.,Bangala Yolanda,Frachette Marie-Joelle,Wagner Ralf,Liljeström Peter,Kraehenbuhl Jean-Pierre,Girard Marc,Goudsmit Jaap,Esteban Mariano,Heeney Jonathan,Sattentau Quentin,McCormack Sheena,Babiker Abdel,Pantaleo Giuseppe,Weber Jonathan

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference10 articles.

1. UNAIDS report on the global AIDS epidemic. Geneva; UNAIDS; 2006.

2. Test of HIV incidence shows continuing HIV transmission in homosexual/bisexual men in England and Wales;Murphy;Commun Dis Public Health,2001

3. http://www.eurovacc.org (last accessed May 22nd, 2007).

4. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria;Ockenhouse;J Infect Dis.,1998

5. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans;Kanesa-thasan;Vaccine,2000

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial;PLOS Pathogens;2020-06-26

2. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial;The Lancet HIV;2019-11

3. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost;Journal of Virology;2019-02

4. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC;Journal of Virology;2019-02

5. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates;Journal of Virology;2018-04-15